| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology
SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the Company received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111. The patent that will issue will provide the Company with both composition of matter protection for CER-1236 and protection for the use of CER-1236 to treat cancer, through 2041. Upon issuance, this patent will provide the most comprehensive protection specific to CER-1236 to date.
The Company also obtained a patent in Japan, which provides protection for the CER platform.The newly allowed U.S. application and issued Japanese patent join 17 other patents and another allowed application, bringing the total to 18 patents and 2 allowed applications covering CER-1236 and its platform technology internationally.
Posted In: CERO
